Insulin produced by the Danish company Novo Nordisk is now available in Georgia, allowing children with type 1 diabetes to access the NovoRapid prescription.

According to the Ministry of Health of Georgia, patients may choose to return to using NovoRapid under the previous treatment scheme or continue their therapy with its analogue, Apidra, manufactured by the French pharmaceutical company Sanofi Aventis.

The ministry also states that those who have been using Apidra from the outset have the option to maintain their current treatment.

The Minister of Health has assured the public that the ministry has taken all necessary measures to ensure that NovoRapid is available in Georgia as swiftly as possible.

Mikheil Sarjveladze, the Minister of Health, emphasised that ongoing communication with Novo Nordisk is actively being maintained to prevent similar issues from arising in the future.

“The delay in delivery was due to problems at the manufacturing plant, which prevented Novo Nordisk from supplying the pre-ordered medication to Georgia on time. However, there was no shortage of insulin in the country, and patients continued their treatment with Apidra, an analogue of NovoRapid,” the Ministry of Health stated.